Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26165421,half-life,CNZ is characterized by short half-life (3-6 h).,Utilization of ionotropic gelation technique for bioavailability enhancement of cinnarizine: in-vitro optimization and in-vivo performance in human. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26165421/),h,3-6,37723,DB00568,Cinnarizine
,7616366,t1/2,Cinnarizine pharmacokinetics after iv administration as a 1.25 mg/mL SBE4-beta-CD solution followed triexponential behavior (t1/2 = 12.6 +/- 0.4 h and CI = 1.4 +/- 0.17 L/h/kg).,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),h,12.6,58177,DB00568,Cinnarizine
,7616366,CI,Cinnarizine pharmacokinetics after iv administration as a 1.25 mg/mL SBE4-beta-CD solution followed triexponential behavior (t1/2 = 12.6 +/- 0.4 h and CI = 1.4 +/- 0.17 L/h/kg).,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),[l] / [h·kg],1.4,58178,DB00568,Cinnarizine
,7616366,Fabs,A very low bioavailability of cinnarizine with a wide interanimal variation was observed after oral administration as a suspension (Fabs = 8 +/- 4%) or capsule containing only cinnarizine (Fabs = 0.8 +/- 0.4%).,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),%,8,58179,DB00568,Cinnarizine
,7616366,Fabs,A very low bioavailability of cinnarizine with a wide interanimal variation was observed after oral administration as a suspension (Fabs = 8 +/- 4%) or capsule containing only cinnarizine (Fabs = 0.8 +/- 0.4%).,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),%,0.8,58180,DB00568,Cinnarizine
,7616366,Fabs,Administration of cinnarizine as a CD complex either as a solution (Fabs = 55-60%) or in a capsule (Fabs = 38 +/- 12%) significantly enhanced the bioavailability.,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),%,55-60,58181,DB00568,Cinnarizine
,7616366,Fabs,Administration of cinnarizine as a CD complex either as a solution (Fabs = 55-60%) or in a capsule (Fabs = 38 +/- 12%) significantly enhanced the bioavailability.,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),%,38,58182,DB00568,Cinnarizine
,20636873,oral bioavailability,"The oral bioavailability of cinnarizine using the PHY formulation was 41%, compared to 19% for the GMO formulation and 6% for an aqueous suspension.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),%,41,58438,DB00568,Cinnarizine
,20636873,oral bioavailability,"The oral bioavailability of cinnarizine using the PHY formulation was 41%, compared to 19% for the GMO formulation and 6% for an aqueous suspension.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),%,19,58439,DB00568,Cinnarizine
,20636873,oral bioavailability,"The oral bioavailability of cinnarizine using the PHY formulation was 41%, compared to 19% for the GMO formulation and 6% for an aqueous suspension.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),%,6,58440,DB00568,Cinnarizine
,20636873,T(max),"The PHY formulation provided a T(max) for cinnarizine of 33 h, with absorption apparent up to 55 h after administration.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),h,33,58441,DB00568,Cinnarizine
,20636873,T(max),"In contrast, the T(max) for the GMO formulation was only 5 h.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),h,5,58442,DB00568,Cinnarizine
,20307656,relative bioavailability,The relative bioavailability of oral administration was 46.4%.,Effect of route of administration on the pharmacokinetics and toxicokinetics of cinnarizine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307656/),%,46.4,59762,DB00568,Cinnarizine
,18514457,retention time,"The retention time of mianserin and cinnarizine was 3.4 and 2.1 min, respectively.",Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514457/),min,3.4,90863,DB00568,Cinnarizine
,18514457,retention time,"The retention time of mianserin and cinnarizine was 3.4 and 2.1 min, respectively.",Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514457/),min,2.1,90864,DB00568,Cinnarizine
,18514457,recovery,"The recovery was 81.3-84.1%, intra- and inter-day precision of the assay at three concentrations were 9.6-11.4% with accuracy of 97.5-101.2% and the lower limit of quantitation (LLOQ) detection was 1.0 ng/ml for mianserin.",Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514457/),%,81.3-84.1,90865,DB00568,Cinnarizine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.34,96056,DB00568,Cinnarizine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.40 to 0.60,96057,DB00568,Cinnarizine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.25,96058,DB00568,Cinnarizine
,2866055,Total body clearance,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[ml] / [kg·min],5 to 12,96059,DB00568,Cinnarizine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,3,96060,DB00568,Cinnarizine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18,96061,DB00568,Cinnarizine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,4,96062,DB00568,Cinnarizine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,10 to 14,96063,DB00568,Cinnarizine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,14 to 25,96064,DB00568,Cinnarizine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,20,96065,DB00568,Cinnarizine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,25,96066,DB00568,Cinnarizine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18 to 20,96067,DB00568,Cinnarizine
excess,2866055,apparent volumes of distribution,They also have relatively large apparent volumes of distribution in excess of 4 L/kg.,Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[l] / [kg],4,96068,DB00568,Cinnarizine
,2866055,elimination half-life,"In patients with alcohol-related liver disease, the elimination half-life of diphenhydramine was increased from 9 to 15 hours, while in patients with chronic renal disease that of chlorpheniramine was very greatly prolonged.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,9 to 15,96069,DB00568,Cinnarizine
,18540159,absolute extraction recovery,"The absolute extraction recovery of cinnarizine and clocinizine (internal standard) from plasma samples were 97% and 89%, respectively.",High-performance liquid chromatographic assay for cinnarizine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540159/),%,97,99191,DB00568,Cinnarizine
,18540159,absolute extraction recovery,"The absolute extraction recovery of cinnarizine and clocinizine (internal standard) from plasma samples were 97% and 89%, respectively.",High-performance liquid chromatographic assay for cinnarizine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540159/),%,89,99192,DB00568,Cinnarizine
,21256961,AUC,"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3058 to 3447,110524,DB00568,Cinnarizine
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,∼6,110525,DB00568,Cinnarizine
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,.0,110526,DB00568,Cinnarizine
,21256961,C(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[mg] / [ml],168 to 265,110527,DB00568,Cinnarizine
,21256961,T(max),"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,1.3-4.5,110528,DB00568,Cinnarizine
,21256961,AUC,"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3807 to 4403,110529,DB00568,Cinnarizine
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],5574,110530,DB00568,Cinnarizine
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],7370,110531,DB00568,Cinnarizine
,32904111,EE %,"Their EE % ranged from 64.36±1.985% to 94.09±1.74%, and their in-vitro release percentages were between 61.82±1.92% and 95.92±1.18%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,64.36,120077,DB00568,Cinnarizine
,32904111,EE %,"Their EE % ranged from 64.36±1.985% to 94.09±1.74%, and their in-vitro release percentages were between 61.82±1.92% and 95.92±1.18%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,94.09,120078,DB00568,Cinnarizine
,32904111,release percentages,"Their EE % ranged from 64.36±1.985% to 94.09±1.74%, and their in-vitro release percentages were between 61.82±1.92% and 95.92±1.18%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,61.82,120079,DB00568,Cinnarizine
,32904111,release percentages,"Their EE % ranged from 64.36±1.985% to 94.09±1.74%, and their in-vitro release percentages were between 61.82±1.92% and 95.92±1.18%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,95.92,120080,DB00568,Cinnarizine
,32904111,PS,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),nm,212.3,120081,DB00568,Cinnarizine
,32904111,PS,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),nm,2150,120082,DB00568,Cinnarizine
,32904111,DI,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),,0.238,120083,DB00568,Cinnarizine
,32904111,DI,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),,1,120084,DB00568,Cinnarizine
,32904111,zeta potential,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mv,-,120085,DB00568,Cinnarizine
,32904111,zeta potential,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mv,57.5,120086,DB00568,Cinnarizine
,32904111,zeta potential,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mv,+,120087,DB00568,Cinnarizine
,32904111,zeta potential,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mv,4.73,120088,DB00568,Cinnarizine
,32904111,mucoadhesive force,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),[dyne] / [102·cm2],169.188,120089,DB00568,Cinnarizine
,32904111,mucoadhesive force,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),[dyne] / [102·cm2],321.212,120090,DB00568,Cinnarizine
,32904111,spreadability,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mm,40,120091,DB00568,Cinnarizine
,32904111,spreadability,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mm,138,120092,DB00568,Cinnarizine
,32904111,drug release,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,81.63,120093,DB00568,Cinnarizine
,32904111,drug release,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,97.78,120094,DB00568,Cinnarizine
,32904111,[AUC]0-24,"The in-vivo pharmacokinetic study illustrated that [AUC]0-24 of F1A was significantly higher than that of tablets at (P< 0.05), equivalent to 703.563±26.470 and 494.256±9.621ɲg.hr/mL respectively.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),[h·ɲg] / [ml],703.563,120095,DB00568,Cinnarizine
,32904111,[AUC]0-24,"The in-vivo pharmacokinetic study illustrated that [AUC]0-24 of F1A was significantly higher than that of tablets at (P< 0.05), equivalent to 703.563±26.470 and 494.256±9.621ɲg.hr/mL respectively.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),[h·ɲg] / [ml],494.256,120096,DB00568,Cinnarizine
,3723361,minimum effective dose,It was found from these results that DL-phenylalanine acted as a competing agent in the GI tract and the minimum effective dose required of DL-phenylalanine might be 1 g for 50 mg of cinnarizine in the cinnarizine-beta-cyclodextrin complex.,Enhancement of bioavailability of cinnarizine from its beta-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723361/),g,1,147149,DB00568,Cinnarizine
,8328998,Cmax,"Cmax was 275 +/- 36 ng/ml, tmax 3.0 +/- 0.5 h, AUC extrapolated to infinity 4437 +/- 948 ng.h/ml and terminal half-life 23.6 +/- 3.2 h.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),[ng] / [ml],275,155297,DB00568,Cinnarizine
,8328998,tmax,"Cmax was 275 +/- 36 ng/ml, tmax 3.0 +/- 0.5 h, AUC extrapolated to infinity 4437 +/- 948 ng.h/ml and terminal half-life 23.6 +/- 3.2 h.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),h,3.0,155298,DB00568,Cinnarizine
,8328998,AUC extrapolated to infinity,"Cmax was 275 +/- 36 ng/ml, tmax 3.0 +/- 0.5 h, AUC extrapolated to infinity 4437 +/- 948 ng.h/ml and terminal half-life 23.6 +/- 3.2 h.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),[h·ng] / [ml],4437,155299,DB00568,Cinnarizine
,8328998,terminal half-life,"Cmax was 275 +/- 36 ng/ml, tmax 3.0 +/- 0.5 h, AUC extrapolated to infinity 4437 +/- 948 ng.h/ml and terminal half-life 23.6 +/- 3.2 h.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),h,23.6,155300,DB00568,Cinnarizine
,8328998,accumulation factor,"At steady state (dose 29), the observed accumulation factor was 2.79 +/- 0.23, being not significantly different from that predicted with the terminal half-life obtained from single dose data, which was 3.37 +/- 0.37.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),,2.79,155301,DB00568,Cinnarizine
,8328998,terminal half-life,"At steady state (dose 29), the observed accumulation factor was 2.79 +/- 0.23, being not significantly different from that predicted with the terminal half-life obtained from single dose data, which was 3.37 +/- 0.37.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),,3.37,155302,DB00568,Cinnarizine
,8328998,AUC0-12,"AUC0-12 for dose 29 was 5074 +/- 1021 ng.h/ml, being not significantly different from the AUC extrapolated to infinity obtained with the single dose.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),[h·ng] / [ml],5074,155303,DB00568,Cinnarizine
,16719539,constant rate,The remainder is released at a constant rate of approximately 5 microg/hour.,Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719539/),[μg] / [h],5,174190,DB00568,Cinnarizine
,16719539,steady state,TTS-S attains that concentration after 6 hours; a steady state of about 100 pg/mL is achieved 8-12 hours after application.,Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719539/),[pg] / [ml],100,174191,DB00568,Cinnarizine
,25448073,half life,"It is also characterized by a short half life of 3-6h, which requires frequent daily administration resulting in poor patient compliance.",Floating lipid beads for the improvement of bioavailability of poorly soluble basic drugs: in-vitro optimization and in-vivo performance in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25448073/),h,3-6,183393,DB00568,Cinnarizine
,32935235,Tmax,"The times at which maximum delamanid levels in plasma were observed (Tmax) after oral administration of the phytantriol, selachyl alcohol and reconstituted milk powder formulations of delamanid to rats were 27 ± 3, 20 ± 4 and 6.5 ± 1.0 h, respectively, compared with the aqueous suspension formulation with a Tmax of 3.4 ± 1 h, which confirms the hypothesis of an extended duration of absorption after administration in non-digestible self-assembling lipids.",Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935235/),h,27,188304,DB00568,Cinnarizine
,32935235,Tmax,"The times at which maximum delamanid levels in plasma were observed (Tmax) after oral administration of the phytantriol, selachyl alcohol and reconstituted milk powder formulations of delamanid to rats were 27 ± 3, 20 ± 4 and 6.5 ± 1.0 h, respectively, compared with the aqueous suspension formulation with a Tmax of 3.4 ± 1 h, which confirms the hypothesis of an extended duration of absorption after administration in non-digestible self-assembling lipids.",Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935235/),h,20,188305,DB00568,Cinnarizine
,32935235,Tmax,"The times at which maximum delamanid levels in plasma were observed (Tmax) after oral administration of the phytantriol, selachyl alcohol and reconstituted milk powder formulations of delamanid to rats were 27 ± 3, 20 ± 4 and 6.5 ± 1.0 h, respectively, compared with the aqueous suspension formulation with a Tmax of 3.4 ± 1 h, which confirms the hypothesis of an extended duration of absorption after administration in non-digestible self-assembling lipids.",Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935235/),h,6.5,188306,DB00568,Cinnarizine
,32935235,Tmax,"The times at which maximum delamanid levels in plasma were observed (Tmax) after oral administration of the phytantriol, selachyl alcohol and reconstituted milk powder formulations of delamanid to rats were 27 ± 3, 20 ± 4 and 6.5 ± 1.0 h, respectively, compared with the aqueous suspension formulation with a Tmax of 3.4 ± 1 h, which confirms the hypothesis of an extended duration of absorption after administration in non-digestible self-assembling lipids.",Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935235/),h,3.4,188307,DB00568,Cinnarizine
<,24065588,Δ r G,"The complex constant, K, was evaluated to be 10(9) orders of magnitude with Δ r G < 0.","Preparation, characterization, and evaluation of dipfluzine-benzoic acid co-crystals with improved physicochemical properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24065588/),,0,206692,DB00568,Cinnarizine
,10479356,half-life,Plasma levels of the prodrugs fell below the limit of detection 5 min after iv infusion with an approximate half-life of 1 min.,A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10479356/),min,1,242594,DB00568,Cinnarizine
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,417.3,244252,DB00568,Cinnarizine
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,251.2,244253,DB00568,Cinnarizine
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,199.1,244254,DB00568,Cinnarizine
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,183.2,244255,DB00568,Cinnarizine
higher,24424300,extraction recoveries,The extraction recoveries of their three concentrations for Dip and its three metabolites were all higher than 71.9%.,Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),%,71.9,244256,DB00568,Cinnarizine
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],59,244257,DB00568,Cinnarizine
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],37,244258,DB00568,Cinnarizine
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],3,244259,DB00568,Cinnarizine
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],55,244260,DB00568,Cinnarizine
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,65,244261,DB00568,Cinnarizine
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,95,244262,DB00568,Cinnarizine
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,190,244263,DB00568,Cinnarizine
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,90,244264,DB00568,Cinnarizine
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],17573,244265,DB00568,Cinnarizine
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],8328,244266,DB00568,Cinnarizine
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],5602,244267,DB00568,Cinnarizine
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],16101,244268,DB00568,Cinnarizine
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,329,244269,DB00568,Cinnarizine
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,767,244270,DB00568,Cinnarizine
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,2364,244271,DB00568,Cinnarizine
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,378,244272,DB00568,Cinnarizine
,17467935,Tmax,"A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%).",A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17467935/),h,36,265937,DB00568,Cinnarizine
,17467935,relative oral bioavailability,"A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%).",A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17467935/),%,344,265938,DB00568,Cinnarizine
,17467935,relative oral bioavailability,"A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%).",A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17467935/),%,117,265939,DB00568,Cinnarizine
,17467935,bioavailability,"A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%).",A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17467935/),%,100,265940,DB00568,Cinnarizine
